JP5991543B2 - Anticancer drug - Google Patents
Anticancer drug Download PDFInfo
- Publication number
- JP5991543B2 JP5991543B2 JP2013182974A JP2013182974A JP5991543B2 JP 5991543 B2 JP5991543 B2 JP 5991543B2 JP 2013182974 A JP2013182974 A JP 2013182974A JP 2013182974 A JP2013182974 A JP 2013182974A JP 5991543 B2 JP5991543 B2 JP 5991543B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- silver
- platinum
- terms
- anticancer agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Description
本発明は、制癌剤に関する。本発明は、さらに詳細には、ごく微量の陰イオン化した銀とナノサイズ化した白金を含有する、９９．９％以上が水である制癌剤であって、この制癌剤を１日に０．８〜１．６リットル飲料水感覚で毎日経口により投与すると、この制癌剤が全身を循環して体内に生じたあらゆる癌細胞のみに作用して、その浸潤ならびに増殖を抑えて消滅させることができ、しかも当該制癌剤は正常細胞にはまったく作用せずに体内の酸化を抑え、過酸化脂質を分解し、好気性細菌および有膜性ウイルスを不活性化して副作用を生じさせることなく、癌を治癒することができる制癌剤に関する。 The present invention relates to an anticancer drug. More specifically, the present invention is an anticancer agent containing a very small amount of anionized silver and nanosized platinum, wherein 99.9% or more is water, When administered orally daily with a 1.6 liter drinking water sensation, this anticancer drug can only be circulated throughout the body and act only on all cancer cells that have formed in the body, suppressing its invasion and proliferation, and disappearing. Anticancer drugs do not act on normal cells at all, suppress oxidation in the body, break down lipid peroxides, inactivate aerobic bacteria and membranous viruses, and cure cancer without causing side effects It relates to a possible anticancer agent.
従来から、癌治療法としては、外科手術、放射線照射、化学療法（抗癌剤）、免疫治療、およびこれらの複合治療法などがある。しかしながら、いずれの方法も、対象となる部位の癌細胞に対する治療法であり、転移した癌細胞や発見できない小さな癌細胞までを治療消滅させることはできず、またいずれの方法も、副作用を抑えることは困難である。
これは、癌を起こすも殺すも、活性酸素といわれるように、いずれの治療法もほとんど活性酸素が関与するからであり、手術後の薬物代謝およびストレスが活性酸素を生じさせ、放射線治療は活性酸素によるものであり、化学療法も活性酸素の力によるものが大部分であり、免疫療法も活性酸素の効果に左右されるものといえる。このように、現在、副作用を生じさせることなく、癌細胞を治療消滅させる方法は見当たらない。
Conventionally, cancer treatment methods include surgery, radiation, chemotherapy (anticancer agent), immunotherapy, and a combination treatment thereof. However, each method is a treatment method for cancer cells at the target site, and it is not possible to treat and extinguish even cancer cells that have metastasized or small cancer cells that cannot be found, and both methods suppress side effects. It is difficult.
This is because, as it is called active oxygen, which causes or kills cancer, both therapies involve almost all active oxygen, and post-operative drug metabolism and stress produce active oxygen, and radiation therapy is active. It is due to oxygen, and most chemotherapy is due to the power of active oxygen, and immunotherapy is also dependent on the effect of active oxygen. Thus, there is currently no method for eliminating cancer cells without causing side effects.
ところで、本発明者は、先に銀および白金を含む改水用固形触媒（不溶出型）を提案した（特許文献１）。この固形触媒を用いて水道水を改質した水を用い、下記のように、マウスにヒト前立腺癌細胞を注入後、飲料水として投与し、９０日間の試験を行った結果を参考に本発明の制癌剤を開発するにいたったものである。
なお、この改質触媒を用いた精製水の２４時間浸漬後の溶出試験を厚生労働省告示２６号に従い行ったが、溶出する成分はなかった。
By the way, this inventor previously proposed a solid catalyst for water reforming (non-eluting type) containing silver and platinum (Patent Document 1). Using the water obtained by modifying tap water using this solid catalyst, human prostate cancer cells were injected into mice as described below, then administered as drinking water, and the present invention was referred to based on the results of a 90-day test. To develop anticancer drugs.
In addition, although the elution test after 24-hour immersion of the purified water using this reforming catalyst was conducted according to Ministry of Health, Labor and Welfare Notification No. 26, there was no component to elute.
ここで、実験に用いた改質水の調製は、次のとおりである。
すなわち、焼成ゼオライトに加工剤（銀担持合成ゼオライト、コロイド状白金および酸化アルミニウム、ケイ素化合物からなるもの）をコートして、加熱硬化した粒状の触媒（改質水１Ｌに当該触媒を４５ｇ浸漬し、２４時間後に測定した溶出試験において検出せず）を、水道水、あるいはミネラル水に８時間以上浸漬して作成したものである。
＜マウスによる生体実験の結果＞
Here, the preparation of the reformed water used in the experiment is as follows.
That is, a calcined zeolite is coated with a processing agent (comprising silver-supporting synthetic zeolite, colloidal platinum, aluminum oxide, and silicon compound), and heat-cured granular catalyst (45 g of the catalyst is immersed in 1 L of reformed water, (Not detected in the elution test measured 24 hours later) was soaked in tap water or mineral water for 8 hours or more.
<Results of biological experiments using mice>
マウス１０匹ずつを３群に分け、１群は癌細胞を注入する６日前から上記改質水を投与し、癌細胞注入後も実験終了まで投与し続けた。２群は、癌細胞注入後から実験終了まで投与、３群はコントロール群として、通常の水道水を投与した。その結果は、次のとおり
である。
Ten mice were divided into 3 groups, and 1 group was administered with the modified water from 6 days before the injection of cancer cells, and continued after the injection of cancer cells until the end of the experiment. Group 2 was administered from the injection of cancer cells until the end of the experiment, and Group 3 was administered with normal tap water as a control group. The results are as follows.
本発明は、従来技術の課題を背景になされたもので、銀イオンおよび白金を含む改水用固形触媒（不溶出型）により水道水を改質した水を用いると、マウスに注入されたヒト前立腺癌細胞が消滅することを見出し、本発明に到達したものである。 The present invention has been made against the background of the problems of the prior art, and when water obtained by modifying tap water with a solid catalyst for water reforming (non-eluting type) containing silver ions and platinum is used, humans injected into mice The inventors have found that prostate cancer cells disappear and have reached the present invention.
本発明は、（ａ）水１リットルに対し、（ｂ）チオ硫酸銀イオンを４０〜２４０ｍｇ（銀換算で２．０８〜１２．４８ｍｇ）と、（ｃ）コロイド状の白金を５０〜３００ｍｇ（白金換算で０．００６〜０．０３６ｍｇ）を添加・混合してなる、制癌剤に関する。
ここで、（ａ）水は、水道水、ミネラル水、精製水、およびその他の飲料水から選ばれた少なくとも１種である。
また、（ｂ）成分のチオ硫酸銀イオンは、式［Ａｇ（Ｓ２Ｏ３）２］３−および／または式［Ａｇ（Ｓ２Ｏ３）６］１０−で表される。
The present invention relates to (a) 1 liter of water, (b) 40 to 240 mg of silver thiosulfate ion (2.08 to 12.48 mg in terms of silver), and (c) 50 to 300 mg of colloidal platinum ( The present invention relates to an anticancer drug obtained by adding and mixing 0.006 to 0.036 mg in terms of platinum.
Here, (a) water is at least 1 sort (s) chosen from tap water, mineral water, purified water, and other drinking water.
Further, (b) component of the silver thiosulfate ions, formula [Ag (S 2 O 3) 2] 3- and / or formula [Ag (S 2 O 3) 6] represented by 10.
本発明の制癌剤は、ごく微量の陰イオン化した銀およびナノサイズ化した白金を含有し、９９．９％以上が水であり、この制癌剤を飲料水感覚で１日に０．８〜１．６リットル飲み続けることにより、正常細胞にはまったく作用せずに、対象となる部位の癌細胞および転移した癌細胞や発見されていない小さな癌細胞までのすべての癌細胞のみに反応し、その浸潤・増殖を抑えて消滅させることができ、しかも治療期間中、さらにその後も副作用が生じることなく、癌を治癒することができる。
また、本発明によれば、抗酸化作用（還元性）、脂質分解性、抗菌性（好気性菌のみ）、抗ウイルス性、および可溶性電極による静電気特性などの性状を有する制癌剤が、全身を循環するため、制癌作用のほか、血管をはじめ各器官が浄化され、体内の酸化防止ができ、腸内細菌のバランスが良好になり、健康体を取り戻すことができる。
The anticancer agent of the present invention contains a very small amount of anionized silver and nanosized platinum, and 99.9% or more is water. By continuing to drink liters, it does not act on normal cells at all, but it reacts only with all cancer cells, including cancer cells at the target site and cancer cells that have metastasized and small cancer cells that have not been discovered. The cancer can be cured by suppressing the growth and disappearing without causing any side effects during the treatment period.
In addition, according to the present invention, an anticancer agent having properties such as antioxidant action (reducing property), lipolytic property, antibacterial property (only aerobic bacteria), antiviral property, and electrostatic property due to a soluble electrode circulates throughout the body. Therefore, in addition to anticancer action, each organ including blood vessels is purified, oxidation in the body can be prevented, the balance of enteric bacteria is improved, and a healthy body can be recovered.
本発明は、（ａ）水１リットルに対し、（ｂ）チオ硫酸銀イオンを銀換算で２．０８〜１２．４８ｍｇと、（ｃ）コロイド状の白金を白金換算で０．００６〜０．０３６ｍｇを添加・混合してなる、制癌剤に関する。
以下、本発明の制癌剤を構成する各成分ごとに説明する。
The present invention relates to (a) 1 liter of water, (b) 2.08 to 12.48 mg of silver thiosulfate ion in terms of silver, and (c) colloidal platinum in the range of 0.006 to 0.004 in terms of platinum. The present invention relates to an anticancer drug comprising 036 mg added and mixed.
Hereinafter, each component constituting the anticancer agent of the present invention will be described.
（ａ）水
本発明に用いられる（ａ）水は、水道水、ミネラル水、精製水、その他の飲料水などから選ばれた少なくとも１種である。また、（ａ）水には、本発明の制癌剤を構成する（ｂ）成分や（ｃ）成分に含まれる水も包含し、（ａ）成分である水を合計すると、本発明の制癌剤に占める（ａ）水の割合は、９９．９％以上となる。
(A) used in the water present invention (a) water, tap water, mineral water, purified water, at least one selected from and other drinking water. In addition, (a) water includes water contained in component (b) and component (c) constituting the anticancer agent of the present invention, and the total amount of water as component (a) occupies the anticancer agent of the present invention. (A) The ratio of water is 99.9% or more.
（ｂ）チオ硫酸銀イオン
（ｂ）チオ硫酸銀中のチオ硫酸銀イオンは、本発明の制癌剤において、次のような性能を有するために使用される。
（１）癌細胞のみに作用して、その浸潤、増殖を抑えることができ、正常細胞にはまったく作用せず、また銀を陰イオン化したため、沈着・蓄積することがなく、さらに塩分とも反応せず、毎日経口より投与することができる。
（２）抗酸化性（還元性）の水溶液で活性酸素を消去する。
（３）浸透力、溶解力の高い水溶液になり、脂質を分解し溶解する。
（４）好気性細菌のみに作用し不活化するが、嫌気性細菌には反応しないため当該嫌気性細菌は増殖する。
（５）有膜性ウイルスを不活化する。
(B) Silver thiosulfate ion (b) The silver thiosulfate ion in silver thiosulfate is used in the anticancer agent of the present invention to have the following performance.
(1) Acts only on cancer cells and can suppress their invasion and proliferation, does not act on normal cells at all, and silver is anionized, so it does not accumulate and accumulate, and reacts with salt. It can be administered orally daily.
(2) The active oxygen is eliminated with an antioxidant (reducing) aqueous solution.
(3) It becomes an aqueous solution with high penetrating power and dissolving power, and decomposes and dissolves lipids.
(4) Acts on and inactivates only aerobic bacteria, but does not react with anaerobic bacteria, so the anaerobic bacteria grow.
(5) Inactivate the membranous virus.
（ａ）チオ硫酸銀イオンは、次の（１）〜（３）いずれかの方法で作成されるが、これらに限定されるものではない。
（１）硝酸銀の溶液にチオ硫酸ソーダの水溶液を加えると白色の沈殿ができる。上澄み液を除去し、洗浄したのち、さらにチオ硫酸ソーダ水溶液を加えていくと沈殿が溶けてチオ硫酸銀イオンの溶液ができる。
（２）硝酸銀の溶液に苛性ソーダの水溶液を加えると黒褐色の酸化銀の沈殿ができる。この上澄液を除去し、充分に洗浄したのち、チオ硫酸ソーダ水溶液を加え、沈殿を溶かすと淡黄色の透明なチオ硫酸銀イオンの水溶液ができる。
（３）酢酸銀（ＣＨ３ＣＯＯＡｇ）の水溶液に亜硫酸ソーダ水溶液、チオ硫酸ソーダ水溶液を順次加えて溶解させると、チオ硫酸銀イオンの水溶液ができる。
(A) The silver thiosulfate ion is prepared by any of the following methods (1) to (3), but is not limited thereto.
(1) When an aqueous solution of sodium thiosulfate is added to a silver nitrate solution, a white precipitate is formed. After removing the supernatant and washing, when sodium thiosulfate aqueous solution is further added, the precipitate dissolves to form a silver thiosulfate ion solution.
(2) When an aqueous solution of caustic soda is added to the silver nitrate solution, black-brown silver oxide is precipitated. After removing this supernatant and thoroughly washing it, a sodium thiosulfate aqueous solution is added and the precipitate is dissolved to produce a pale yellow transparent silver thiosulfate aqueous solution.
(3) A sodium sulfite aqueous solution and a sodium thiosulfate aqueous solution are sequentially added and dissolved in an aqueous solution of silver acetate (CH 3 COOAg) to form an aqueous solution of silver thiosulfate ions.
（ｂ）成分におけるチオ硫酸銀イオンは、式［Ａｇ（Ｓ２Ｏ３）２］３−および／または式［Ａｇ（Ｓ２Ｏ３）６］１０−で表されることが好ましい。
上記の方法でチオ硫酸イオンＳ２Ｏ３ ２−の濃度が低いときは［Ａｇ（Ｓ２Ｏ３）２］３−に、チオ硫酸イオンＳ２Ｏ３ ２−の濃度が高いときは［Ａｇ（Ｓ２Ｏ３）６］１０−になる。
（ｂ）チオ硫酸銀イオンは、（ａ）水１リットルに対し、銀換算で２．０８〜１２．４８ｍｇ）、好ましくは銀換算で２．１２〜９．３６ｍｇであり、２．０８ｍｇ未満では癌細胞の浸潤、増殖を抑える力が不足し、一方１２．４８ｍｇを超えても、制癌効果が変わらないため経済的ではない。
The silver thiosulfate ion in the component (b) is preferably represented by the formula [Ag (S 2 O 3 ) 2 ] 3− and / or the formula [Ag (S 2 O 3 ) 6 ] 10− .
When the concentration of thiosulfate ion S 2 O 3 2− is low in the above method, [Ag (S 2 O 3 ) 2 ] 3− is used. When the concentration of thiosulfate ion S 2 O 3 2− is high, [Ag (S 2 O 3 ) 6 ] 10− .
(B) Silver thiosulfate ion (a) is 2.08 to 12.48 mg in terms of silver per 1 liter of water), preferably 2.12 to 9.36 mg in terms of silver, and less than 2.08 mg The ability to suppress infiltration and proliferation of cancer cells is insufficient, and if it exceeds 12.48 mg, the anticancer effect does not change, which is not economical.
（ｃ）水性コロイド状白金
（ｃ）水性コロイド状白金は、白金の平均一次粒子径が５ｎｍ以下で、水中に分散し安定している。本発明において、（ｃ）水性コロイド状白金は、（ｂ）成分との併用で効果が増し、あらゆる部位の癌細胞の浸潤、増殖を抑えて消滅させる作用が増大するものと考えられる。
本発明に用いられる（ｃ）水性コロイド状白金は、超微粒子状白金であり、自体積の数百倍の水素および酸素を吸蔵することができ、これが原子状になっていて非常に活性に富み、還元および酸化の触媒として働き、また（ｂ）成分の銀イオンとの電位差による静電気効果も考えられる。
(C) Aqueous colloidal platinum (c) The aqueous colloidal platinum has an average primary particle diameter of platinum of 5 nm or less and is dispersed and stable in water. In the present invention, (c) aqueous colloidal platinum is considered to increase the effect when used in combination with component (b), and to increase the action of suppressing and extinguishing the infiltration and proliferation of cancer cells at all sites.
The (c) aqueous colloidal platinum used in the present invention is ultrafine platinum, and can absorb several hundred times as much hydrogen and oxygen as its own volume. It acts as a catalyst for reduction and oxidation, and an electrostatic effect due to a potential difference from the silver ion of component (b) is also conceivable.
（ｃ）水性コロイド状白金は、例えば次のような方法により作成されるが、この方法に限定されるものではない。
（１）塩化白金酸「Ｈ２[ＰｔＣｌ６]・６Ｈ２Ｏ」 １ｇを純水で希釈して３７７ｇを作成する。この液は、白金として０．１％含有する塩化白金酸水溶液である。
（２）クエン酸ナトリウムの１％水溶液を作成する。
（３）純水５００ｇを煮沸して、水中の溶存酸素を取り除いたのち、（１）の塩化白金水溶液１００ｇを加え、再び煮沸させ、これに（２）のクエン酸ナトリウム１％水溶液２００ｇを加えて煮沸を続けると、液は徐々に淡黄色→褐色→黒色となり、約２時間後に色の変化がなくなり、白金が約０．０１２％の水性コロイド状白金ができ、これを１０分の１に濃縮すると、白金が約０．１２％の水性コロイド状白金ができる。
(C) The aqueous colloidal platinum is produced by, for example, the following method, but is not limited to this method.
(1) 1 g of chloroplatinic acid “H 2 [PtCl 6 ] · 6H 2 O” is diluted with pure water to prepare 377 g. This solution is a chloroplatinic acid aqueous solution containing 0.1% as platinum.
(2) Make a 1% aqueous solution of sodium citrate.
(3) After boiling 500 g of pure water to remove dissolved oxygen in water, add 100 g of platinum chloride aqueous solution of (1) and boil again, and add 200 g of 1% aqueous solution of sodium citrate (2) to this When boiling is continued, the liquid gradually changes from pale yellow to brown to black, and after about 2 hours, the color change disappears, and an aqueous colloidal platinum with about 0.012% platinum is formed, which is reduced to 1/10. Concentration produces an aqueous colloidal platinum with about 0.12% platinum.
本発明において、（ｃ）水性コロイド状白金は、（ａ）水１リットルに対し、白金換算で０．００６〜０．０３６ｇ、好ましくは白金換算で０．０１〜０．０３ｍｇであり、０．００６ｍｇ未満では（ｂ）成分との併用で癌細胞の浸潤・増殖を抑える効果が不足し、一方０．０３６ｍｇを超えても効果が変わらないと考えられる。 In the present invention, (c) aqueous colloidal platinum is 0.006 to 0.036 g in terms of platinum, preferably 0.01 to 0.03 mg in terms of platinum, with respect to 1 liter of water (a). If it is less than 006 mg, the effect of suppressing the invasion / proliferation of cancer cells by the combined use with the component (b) is insufficient.
なお、本発明の制癌剤には、上記（ａ）〜（ｃ）成分のほか、必要に応じて水性コロイド状金などを含むこともできる。 In addition to the above components (a) to (c), the anticancer agent of the present invention can also contain aqueous colloidal gold as necessary.
本発明の制癌剤の調製方法としては、（ａ）成分に（ｂ）〜（ｃ）成分を加えて、攪拌・混合する。また、必要に応じてこれにさらに（ａ）水を加えて攪拌・混合する。 As a method for preparing the anticancer agent of the present invention, the components (b) to (c) are added to the component (a), and the mixture is stirred and mixed. Further, if necessary, (a) water is further added thereto, followed by stirring and mixing.
本発明の制癌剤は、（ａ）水は、（ｂ）成分および（ｃ）成分の添加により、（ａ）水が改質されて制癌剤水になるものといえる。このため、本発明の制癌剤水を、一日に０．８〜１．６リットル飲用して全身を循環させることが必要であり、通常の飲料水感覚で毎日飲用することができる。
この改質された水は、抗酸化性（還元性）、脂質分解性、抗菌性（好気性菌のみ）、抗ウイルス性（有膜のみ）、および可溶電極による静電気性などの性状を有する制癌剤となり、正常細胞には作用せず、固定しない根無し草のような癌細胞および治療後に副作用が生じることがなく、きわめて安全性の高い制癌剤となり、さらに各器官を浄化し、酸化を抑え、腸内細菌のバランスを良好にして健康体を取り戻す飲料水になると考えられる。
In the anticancer agent of the present invention, (a) water can be said to be (a) water that is modified by addition of the (b) component and the (c) component to become anticancer agent water. For this reason, it is necessary to drink 0.8 to 1.6 liters of the anticancer drug water of the present invention per day and circulate the whole body, and it can be drunk daily with a normal drinking water sensation.
This modified water has properties such as antioxidant (reducing), lipolytic, antibacterial (aerobic bacteria only), antiviral (film only), and electrostatic properties with soluble electrodes It becomes an anticancer agent, does not act on normal cells, does not fix cancer cells like rootless grass, and does not cause side effects after treatment, it becomes an extremely safe anticancer agent, further purifies each organ, suppresses oxidation, reduces intestine It is thought to be a drinking water that restores a healthy body by improving the balance of bacteria.
以下、実施例を挙げ、本発明をさらに具体的に説明するが、本発明は、特許請求の範囲を越えない限り、以下の実施例に限定されるものではない。 EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to the following examples unless it exceeds the scope of the claims.
参考例１(制癌剤の作成)
＜制癌剤（１）＞
水道水１リットルに、下記（ｂ）成分７０ｍｇ（銀換算で約３．６ｍｇ）と、下記（ｃ）成分を８０ｍｇ（白金換算で約０００９６ｍｇ）を添加して、制癌剤（１）を調製した。
なお、（ｂ）成分、（ｃ）成分の調製は次のようにして実施した。
＜（ｂ）成分の調製＞
硝酸銀溶解水に５％苛性ソーダ液を加え、褐色の沈殿をつくり、上澄み水を除去し、純水で３回洗浄したのち、無水チオ硫酸ソーダを添加、純水を加えて調整し、銀約５．２％のチオ硫酸銀溶液を作成し、さらに水を加えて銀分を調整した。
＜（ｃ）成分の調製＞
塩化白金酸水溶液に、溶存酸素を除去した純水に溶解させたクエン酸ナトリウム１％溶液加えて煮沸し、白金約０．０１２％の白金コロイドを作成し、濃縮して白金分を調整した。
＜制癌剤（２）＞
水道水１リットルに、上記（ｂ）成分１６０ｍｇ（銀換算で約８．３２ｍｇ）と、上記（ｃ）成分を１５０ｍｇ（白金換算で約０.０１８ｍｇ）を添加して、制癌剤（２）を調製した。
Reference Example 1 (Creation of anticancer drug)
<Anticancer agent (1)>
To 1 liter of tap water, 70 mg (about 3.6 mg in terms of silver) of the following component (b) and 80 mg (about 9096 mg in terms of platinum) of the following component (c) were added to prepare the anticancer drug (1).
The components (b) and (c) were prepared as follows.
<Preparation of component (b)>
Add 5% caustic soda solution to silver nitrate dissolved water to form a brown precipitate, remove the supernatant water, wash with pure water three times, add anhydrous sodium thiosulfate, add pure water and adjust to about 5 silver A 2% silver thiosulfate solution was prepared, and water was further added to adjust the silver content.
<Preparation of component (c)>
A 1% sodium citrate solution dissolved in pure water from which dissolved oxygen was removed was added to a chloroplatinic acid aqueous solution and boiled to prepare a platinum colloid of about 0.012% platinum, and concentrated to adjust the platinum content.
<Anticancer agent (2)>
To 1 liter of tap water, 160 mg of the component (b) (approximately 8.32 mg in terms of silver) and 150 mg of the component (c) (approximately 0.018 mg in terms of platinum) are added to prepare the anticancer drug (2). did.
実施例１
参考例１で得られた制癌剤（１）および（２）を用いて、酸化還元電位を測定した。対照として、水道水および市販のミネラル水を使用した。結果を表１に示す。
表１から、本発明の制癌剤は、ｐＨが原水と変わらず、酸化還元電位が大幅に下がり、還元力が証明された。
Example 1
Using the anticancer agents (1) and (2) obtained in Reference Example 1, the redox potential was measured. Tap water and commercially available mineral water were used as controls. The results are shown in Table 1.
From Table 1, the pH of the anticancer drug of the present invention was the same as that of the raw water, the oxidation-reduction potential was greatly lowered, and the reducing power was proved.
実施例２
本発明の制癌剤の抗菌性を調べるため、上記制癌剤（１）を用いて、好気性細菌の大腸菌血清型Ｏ−１５７およびメチシリル耐性黄色ブドウ球菌、ならびに嫌気性細菌の酵母菌の菌液を添加し、６時間および２４時間保存後にその生菌数を測定した。
なお、対照として、煮沸した水道水を使用した。結果を表４に示す。
Example 2
In order to investigate the antibacterial activity of the anticancer agent of the present invention, using the above anticancer agent (1), an aerobic bacterial Escherichia coli serotype O-157 and a methylsilyl-resistant Staphylococcus aureus, and an anaerobic bacterial yeast are added. The viable cell count was measured after storage for 6 hours and 24 hours.
In addition, boiled tap water was used as a control. The results are shown in Table 4.
表４の結果、本発明の制癌剤は、好気性細菌に対して強い抗菌性を示し、嫌気性細菌に対しては、逆に増殖性を示している。 As a result of Table 4, the anticancer agent of the present invention exhibits strong antibacterial properties against aerobic bacteria, and conversely exhibits growth properties against anaerobic bacteria.
実施例３
本発明の制癌剤の脂質溶解性を調べるため、牛脂と菜種油を用意し、制癌剤（１）、（２）を用いて、次のような試験を行った。
（１）制癌剤（１）を透明容器に２００ｃｃ取り、これに牛脂を熱で溶解したものを２ｇ添加し、軽く撹拌して混ぜ合わせ、２４時間、目視で観察した。最初、制癌剤に浮いていた牛脂が時間が経過すると、徐々に乳白色になり、乳化されたような状態になった。これを２４時間後に別の容器に移し、元の容器の内面を調べた結果、牛脂の付着はほとんど見られなかった。
（２）制癌剤（２）を同じく、透明容器に２００ｃｃ取り、これに菜種油を１８０℃で２時間加熱し、酸化の進んだ菜種油を２ｇ添加し、軽く撹拌して混ぜ合わせ、３６時間、目視で観察した。これを３６時間後に別の容器に移し、元の容器に４０℃のぬるま湯を入れて観察した結果、油の浮き膜は見られなかった。
以上の結果から、脂質が制癌剤により徐々に分解、溶解して各器官に付着・堆積しないものと考えられる。
Example 3
In order to examine the lipid solubility of the anticancer agent of the present invention, beef tallow and rapeseed oil were prepared, and the following tests were conducted using the anticancer agents (1) and (2).
(1) 200 cc of anticancer drug (1) was taken in a transparent container, 2 g of beef tallow dissolved in heat was added thereto, and the mixture was lightly stirred and mixed, and observed visually for 24 hours. At first, the beef tallow floated on the anticancer drug gradually became milky and gradually emulsified as time passed. After 24 hours, this was transferred to another container, and as a result of examining the inner surface of the original container, almost no beef tallow was observed.
(2) Similarly, take 200 cc of the anticancer drug (2) in a transparent container, heat rapeseed oil at 180 ° C. for 2 hours, add 2 g of rapeseed oil that has been oxidized, mix gently, and mix for 36 hours visually. Observed. This was transferred to another container after 36 hours, and warm water of 40 ° C. was placed in the original container and observed, and as a result, no oil floating film was observed.
From the above results, it is considered that lipid is gradually decomposed and dissolved by the anticancer agent and does not adhere to and accumulate on each organ.
実施例４
本発明の制癌剤の乳癌細胞ＭＣＦ−７と肺癌細胞Ａ５４９の増殖抑制作用を調べた。
まず、制癌剤を細胞培地で１５倍に希釈するため、あらかじめ下記のように、試験用制癌剤で１５倍濃度にした制癌剤を、実験１、実験２、それぞれ、５種作成した。
Example 4
The anti-proliferative action of breast cancer cell MCF-7 and lung cancer cell A549 of the anticancer agent of the present invention was examined.
First, in order to dilute the anticancer agent 15 times with the cell culture medium, five types of anticancer agents, which were previously made 15-fold concentration with the test anticancer agent, were prepared as follows.
＜実験１＞
試験前日に、乳癌細胞MCF7 (2,000 cells/well)と肺癌細胞A549 (500
cells/well)を、それぞれ、９６well plateに播種した。
実験当日に、制癌剤濃縮液を細胞培地で１５倍に希釈し、個々のwellに１５０μl加えた。陽性コントロールとして、１ng/ｍl、TGF-βを陰性コントロールとして、ミリQ水を用いた。その後、６日間、細胞培養を行った。細胞培養終了後、MTT法により、５７０ｎｍと６２０ｎｍの吸光度を測定することで、細胞の生存率を測定した。コントロールとして、０日目の細胞数もＭＴＴ法により測定した。個々の濃度で３回測定し、図１〜２にその平均±ＳＤで表示した。
<Experiment 1>
The day before the test, breast cancer cells MCF7 (2,000 cells / well) and lung cancer cells A549 (500
cells / well) were seeded in a 96-well plate.
On the day of the experiment, the anticancer drug concentrate was diluted 15-fold with cell culture medium, and 150 μl was added to each well. As a positive control, 1 ng / ml, and TGF-β as a negative control, Milli-Q water was used. Thereafter, cell culture was performed for 6 days. After completion of cell culture, the cell viability was measured by measuring absorbance at 570 nm and 620 nm by the MTT method. As a control, the number of cells on day 0 was also measured by the MTT method. The measurement was performed three times at each concentration, and the average ± SD is shown in FIGS.
ここで、表５に、実験１における１５倍希釈後の制癌剤試験名および成分量／Ｌを示す。
なお、それぞれの制癌剤試験名[サンプル番号（２）〜（６）]は、次のようにして調製した。
（２）銀換算で約７８ｍｇのチオ硫酸銀イオンおよび白金換算で約０，３６ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約５．２ｍｇおよび白金換算で約０．０２４ｍｇの液を調製した。
（３）銀換算で約１５．６ｍｇのチオ硫酸銀イオンおよび白金換算で約０，０７２ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約１．０４ｍｇおよび白金換算で約０．００４８ｍｇの液を調製した。
（４）銀換算で約３．１２ｍｇのチオ硫酸銀イオンおよび白金換算で約０，０１４４ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約０．２１ｍｇおよび白金換算で約０．０１４４ｍｇの液を調製した。
（５）銀換算で約０．６２ｍｇのチオ硫酸銀イオンおよび白金換算で約０，０２８ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約０．０４２ｍｇおよび白金換算で約０．０００２ｍｇの液を調製した。
（６）銀換算で約０．０１２ｍｇのチオ硫酸銀イオンおよび白金換算で約０．０００５６ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約０．００８ｍｇおよび白金換算で約０．００００４ｍｇの液を調製した。
Here, Table 5 shows the anticancer drug test name and component amount / L after 15-fold dilution in Experiment 1.
In addition, each anticancer agent test name [sample number (2)-(6)] was prepared as follows.
(2) About 78 mg of silver thiosulfate ion in terms of silver and about 0.36 mg of colloidal platinum in terms of platinum were diluted 15 times with water, and about 5.2 mg in terms of silver and about 0.024 mg in terms of platinum A liquid was prepared.
(3) About 15.6 mg of silver thiosulfate ion in terms of silver and about 0.072 mg of colloidal platinum in terms of platinum are diluted 15 times with water, and about 1.04 mg in terms of silver and about 0.00 in terms of platinum. A solution of 0048 mg was prepared.
(4) About 3.12 mg of silver thiosulfate ion in terms of silver and about 0.0144 mg of colloidal platinum in terms of platinum were diluted 15 times with water, and about 0.21 mg in terms of silver and about 0.001 in terms of platinum. A liquid of 0144 mg was prepared.
(5) About 0.62 mg of silver thiosulfate ion in terms of silver and about 0.028 mg of colloidal platinum in terms of platinum are diluted 15 times with water, and about 0.042 mg in terms of silver and about 0.02 in terms of platinum. A 0002 mg solution was prepared.
(6) About 0.012 mg of silver thiosulfate ion in terms of silver and about 0.00056 mg of colloidal platinum in terms of platinum are diluted 15-fold with water, and about 0.008 mg in terms of silver and about 0.00 in terms of platinum. 00004 mg of liquid was prepared.
＜実験１の結果＞
濃縮制癌剤を１５倍希釈した制癌剤５．２ｍｇ／Ｌの場合、細胞増殖抑制がＮＣＦ７ならびにＡ５４９細胞で認められた。Ａ５４９細胞では、濃縮制癌剤を１５倍に希釈した制癌剤１．０４ｍｇ／Ｌの場合も、細胞増殖抑制効果が観察された。他の用量では、細胞増殖抑制効果が認められなかった。一方、ＭＣＦ７では、１５倍希釈した制癌剤５．２ｍｇ／Ｌ以外は、まったく細胞増殖抑制効果が観察されなかった（図１〜２）。
<Result of Experiment 1>
In the case of the anticancer drug 5.2 mg / L in which the concentrated anticancer drug was diluted 15-fold, cell growth suppression was observed in NCF7 and A549 cells. In A549 cells, the cell growth inhibitory effect was also observed in the case of 1.04 mg / L of the anticancer drug obtained by diluting the concentrated anticancer drug 15 times. At other doses, no cytostatic effect was observed. On the other hand, with MCF7, no cell growth inhibitory effect was observed except for the anticancer drug 5.2 mg / L diluted 15 times (FIGS. 1-2).
＜実験２＞
試験前日に、乳癌細胞MCF7 (2,000 cells/well)と肺癌細胞A549 (500
cells/well)を、それぞれ、９６well plateに播種した。
実験当日に、制癌剤濃縮液を細胞培地で１５倍に希釈し、個々のwellに１５０μl加えた。陽性コントロールとして、１ng/ｍＬ、TGF-βを陰性コントロールとして、ミリQ水を用いた。その後、６日間、細胞培養を行った。細胞培養終了後、MTT法により、５７０ｎｍと６２０ｎｍの吸光度を測定することで、細胞の生存率を測定した。コントロールとして、０日目の細胞数もＭＴＴ法により測定した。個々の濃度で３回測定し、図３〜４にその平均±ＳＤで表示した。また、表６に、１５倍希釈後の制癌剤試験名および成分量／Ｌを示す。
<Experiment 2>
The day before the test, breast cancer cells MCF7 (2,000 cells / well) and lung cancer cells A549 (500
cells / well) were seeded in a 96-well plate.
On the day of the experiment, the anticancer drug concentrate was diluted 15-fold with cell culture medium, and 150 μl was added to each well. As a positive control, 1 ng / mL and TGF-β as a negative control were used Milli-Q water. Thereafter, cell culture was performed for 6 days. After completion of cell culture, the cell viability was measured by measuring absorbance at 570 nm and 620 nm by the MTT method. As a control, the number of cells on day 0 was also measured by the MTT method. The measurement was performed three times at each concentration, and the average ± SD is shown in FIGS. Table 6 shows the anticancer drug test name and component amount / L after 15-fold dilution.
なお、それぞれの制癌剤試験名[サンプル番号（２）〜（６）]は、次のようにして調製した。
（２）銀換算で約５２ｍｇのチオ硫酸銀イオンおよび白金換算で約０，５４ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約３．４７ｍｇおよび白金換算で約０．０３６ｍｇの液を調製した。
（３）銀換算で約１０．４ｍｇのチオ硫酸銀イオンおよび白金換算で約０，０３６ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約０．６９ｍｇおよび白金換算で約０．００６４ｍｇの液を調製した。
（４）銀換算で約２．０８ｍｇのチオ硫酸銀イオンおよび白金換算で約０，０１８ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約０．４４ｍｇおよび白金換算で約０．００１２ｍｇの液を調製した。
（５）銀換算で約０．４１ｍｇのチオ硫酸銀イオンおよび白金換算で約０，００３６ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約０．０３ｍｇおよび白金換算で約０．０００２４ｍｇの液を調製した。
（６）銀換算で約０．８２ｍｇのチオ硫酸銀イオンおよび白金換算で約０．０００７２ｍｇのコロイド状白金を水で１５倍に希釈し、銀換算で約０．００６ｍｇおよび白金換算で約０．００００４８ｍｇの液を調製した。
In addition, each anticancer agent test name [sample number (2)-(6)] was prepared as follows.
(2) About 52 mg of silver thiosulfate ion in terms of silver and about 0.54 mg of colloidal platinum in terms of platinum were diluted 15 times with water, and about 3.47 mg in terms of silver and about 0.036 mg in terms of platinum A liquid was prepared.
(3) About 10.4 mg of silver thiosulfate ion in terms of silver and about 0.036 mg of colloidal platinum in terms of platinum are diluted 15 times with water, and about 0.69 mg in terms of silver and about 0.00 in terms of platinum. A 0064 mg solution was prepared.
(4) About 2.08 mg of silver thiosulfate ion in terms of silver and about 0.018 mg of colloidal platinum in terms of platinum are diluted 15-fold with water, and about 0.44 mg in terms of silver and about 0.04 in terms of platinum. A solution of 0012 mg was prepared.
(5) About 0.41 mg of silver thiosulfate ion in terms of silver and about 0,0036 mg of colloidal platinum in terms of platinum are diluted 15-fold with water, and about 0.03 mg in terms of silver and about 0.03 in terms of platinum. 0,024 mg of liquid was prepared.
(6) About 0.82 mg of silver thiosulfate ion in terms of silver and about 0.00072 mg of colloidal platinum in terms of platinum are diluted 15-fold with water, and about 0.006 mg in terms of silver and about 0.00 in terms of platinum. A solution of 000048 mg was prepared.
＜実験２の結果＞
ＭＣＦ７およびＡ５４９細胞ともに、制癌剤３．４７ｍｇ／Ｌのみで、細胞増殖抑制効果が認められた。しかしながら、低濃度の制癌剤では、細胞増殖抑制は観察できなかった。
<Result of Experiment 2>
In both MCF7 and A549 cells, the antiproliferative effect was observed only with the anticancer drug 3.47 mg / L. However, cell growth inhibition could not be observed with low concentrations of anticancer drugs.
＜考察＞
実験１および実験２の結果より、制癌剤５．２ｍｇ／Ｌおよび制癌剤３．４７ｍｇ／Ｌでは、乳癌細胞および肺癌細胞において、細胞増殖抑制作用を有していることがわかる。
<Discussion>
From the results of Experiment 1 and Experiment 2, it can be seen that the anticancer drug 5.2 mg / L and the anticancer drug 3.47 mg / L have a cell growth inhibitory action in breast cancer cells and lung cancer cells.
実施例５（本発明の制癌剤の毒性試験）
水道水１Ｌに、（ｂ）成分を３６０ｍｇ（銀換算で約１８．７ｍｇ）、（ｃ）成分を７５０ｍｇ（白金換算で約０．０９ｍｇ）添加・混合した濃度の高い制癌剤のマウスにおける単回経口投与毒性試験を行った。
なお、（ｂ）成分、（ｃ）成分の調製は次のようにして実施した。
＜（ｂ）成分の調製＞
硝酸銀溶解水に５％苛性ソーダ液を加え、褐色の沈殿をつくり、上澄み水を除去し、純水で３回洗浄したのち、無水チオ硫酸ソーダを添加、純水を加えて調整し、１２ｇチオ硫酸銀溶液（銀換算で約６２０ｍｇ）を調製した。
＜（ｃ）成分の調製＞
塩化白金酸水溶液に、溶存酸素を除去した純水に溶解させたクエン酸ナトリウム１％水溶液加えて煮沸し、５００ｇのコロイド状白金（白金換算で約０．０９ｍｇ）を調製した。
Example 5 (Toxicity test of anticancer drug of the present invention)
A single oral dose in a high-concentration anticancer drug mouse in which 360 mg of component (b) (about 18.7 mg in terms of silver) and 750 mg (about 0.09 mg in terms of platinum) of component (c) were added to 1 L of tap water and mixed. A dose toxicity study was conducted.
The components (b) and (c) were prepared as follows.
<Preparation of component (b)>
Add 5% caustic soda solution to silver nitrate dissolved water to form brown precipitate, remove supernatant water, wash with pure water 3 times, add anhydrous sodium thiosulfate, add pure water to adjust, 12g thiosulfuric acid A silver solution (about 620 mg in terms of silver) was prepared.
<Preparation of component (c)>
A 1% aqueous solution of sodium citrate dissolved in pure water from which dissolved oxygen was removed was added to the chloroplatinic acid aqueous solution and boiled to prepare 500 g of colloidal platinum (about 0.09 mg in terms of platinum).
試験に用いたマウスの数は、雌・雄各６匹で、投与時（４時間絶食後）の体重は雄２７．０〜２９．４ｇ、雌２５．０〜２５．７ｇであった。
濃制癌剤２，０００ｍｇ／ｋｇの１用量を雌、雄マウスに単回経口投与し、１４日間にわたり観察した。
その結果、雌・雄とも死亡例は認められず、一般状態にも異常は認められなかった。体重についても、雌・雄ともに順調な増加を示した。また、観察終了後、部検を行い、外部所見、胸腔内および腹腔内臓についても、肉眼的に観察したが、異常所見は認められなかった。
以上の結果より、本発明の制癌剤のＬＤ５０値は、雌・雄マウス、いずれも２，０００ｍｇ／ｋｇ以上と判定された。
観察期間中の体重変化を表７に示す。
The number of mice used in the test was 6 females and 6 males, and the body weights at the time of administration (after fasting for 4 hours) were 27.0-29.4 g males and 25.0-25.7 g females.
A dose of 2,000 mg / kg of a concentrated anticancer drug was orally administered to female and male mice once and observed over 14 days.
As a result, there were no deaths in both females and males, and no abnormalities were observed in the general condition. Body weight also showed a steady increase in both females and males. In addition, after the observation was completed, a partial examination was performed, and external findings, intrathoracic and abdominal viscera were also observed macroscopically, but no abnormal findings were observed.
From the above results, the LD50 value of the anticancer agent of the present invention was determined to be 2,000 mg / kg or more for both female and male mice.
Table 7 shows changes in body weight during the observation period.
本発明によれば、ごく微量の陰イオン化した銀とナノサイズ化した白金を含有し、９９．９％以上が水である制癌剤であり、これを１日に０．８〜１．６リットル飲料水感覚で毎日経口により投与すると、この制癌剤が全身を循環して体内に生じたあらゆる癌細胞のみに作用して、その浸潤ならびに増殖を抑えて消滅させることができ、しかも当該制癌剤は正常細胞にはまったく作用せずに体内の酸化を抑え、過酸化脂質を分解し、好気性細菌および有膜性ウイルスを不活性化して副作用を生じさせることなく治癒することができ、制癌剤として有用であるほか、血管をはじめ各器官が浄化され、体内の酸化防止ができ、腸内細菌のバランスが良好になり、健康体を取り戻すことができるから、健康水としても利用することができる。
According to the present invention, it is an anticancer agent containing a very small amount of anionized silver and nanosized platinum, and 99.9% or more of water, which is a 0.8 to 1.6 liter beverage per day. When administered orally daily with a water sensation, this anticancer agent can only act on all cancer cells that have circulated throughout the body and suppress their invasion and proliferation, and the anticancer agent can become normal cells. Inhibits the body's oxidation without acting at all, breaks down lipid peroxide, inactivates aerobic bacteria and membranous virus, and cures without causing side effects, and is useful as an anticancer agent Since blood vessels and other organs are purified, oxidation in the body can be prevented, the balance of enteric bacteria is improved, and a healthy body can be regained, it can also be used as healthy water.
Claims (3)
［Ａｇ（Ｓ ２ Ｏ ３ ） ６ ］ １１− で表される請求項１または２に記載の制癌剤。
(B) The component silver thiosulfate ion is represented by the formula [Ag (S 2 O 3 ) 2 ] 3- and / or formula
[Ag (S 2 O 3) 6] anticancer agent according to claim 1 or 2 represented by 11.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013182974A JP5991543B2 (en) | 2013-09-04 | 2013-09-04 | Anticancer drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013182974A JP5991543B2 (en) | 2013-09-04 | 2013-09-04 | Anticancer drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015048348A JP2015048348A (en) | 2015-03-16 |
| JP5991543B2 true JP5991543B2 (en) | 2016-09-14 |
Family
ID=52698644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013182974A Active JP5991543B2 (en) | 2013-09-04 | 2013-09-04 | Anticancer drug |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5991543B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017190313A (en) * | 2016-04-15 | 2017-10-19 | 市川 好男 | Immunity-activating aqueous solution |
| JP7048167B2 (en) * | 2016-09-02 | 2022-04-05 | 好男 市川 | Treatment of lifestyle-related diseases Water and treatment methods for lifestyle-related diseases |
| JP7086363B1 (en) | 2022-01-19 | 2022-06-20 | 株式会社ミスターウォーターマン | A composition for growing Akkermansia muciniphila that increases the intestinal bacterium Akkermansia, which strengthens the intestinal mucosal barrier, and improves the intestinal environment. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3411195B2 (en) * | 1997-08-18 | 2003-05-26 | 栄一 築地 | Active oxygen remover |
| KR100331952B1 (en) * | 2000-11-23 | 2002-04-09 | 최수일 | The Composition Of Multipurpose High-Functional Alkali Solution, Preparation Thereof, And For The Use Of Nonspecific Immunostimulator |
| JP2007023222A (en) * | 2005-07-20 | 2007-02-01 | Oshima Shipbuilding Co Ltd | Coating composition and method for forming disinfecting film using the composition and used for seawater |
| JP2007332039A (en) * | 2006-06-12 | 2007-12-27 | Sumiya Yoji | Algicide for red tide and method of killing algae for red tide |
| JP5744531B2 (en) * | 2011-01-14 | 2015-07-08 | 株式会社日板研究所 | Solid catalyst for reformed water, method for producing reformed water, and reformed water |
-
2013
- 2013-09-04 JP JP2013182974A patent/JP5991543B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015048348A (en) | 2015-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bayrami et al. | A facile ultrasonic-aided biosynthesis of ZnO nanoparticles using Vaccinium arctostaphylos L. leaf extract and its antidiabetic, antibacterial, and oxidative activity evaluation | |
| JP5991543B2 (en) | Anticancer drug | |
| AU2016259438A1 (en) | Mitigation of animal and plant diseases using bioavailable minerals | |
| JP2004530659A (en) | Methods and formulations for antitumor and antimetastatic effects | |
| Tolesani Júnior et al. | Haff disease associated with the ingestion of the freshwater fish Mylossoma duriventre (pacu-manteiga) | |
| US10597315B2 (en) | Method of disinfection of drinking water using ozone and silver cations | |
| CN102309508A (en) | Application of drug composition in preparation of drugs for treating anemia | |
| CN109498595B (en) | Ferritin-metal nanoparticles and application thereof | |
| JP2003508454A (en) | Tumor remission method and composition, and cancer suppression method and composition | |
| CN106178062A (en) | A kind of material with durable antibiotic performance and preparation method thereof | |
| Liu et al. | Self-assembled copper tannic acid nanoparticles: A powerful nano-bactericide by valence shift of copper | |
| CN103655593B (en) | Composite medicine preparation for prevention and treatment of bacterium and virus polyinfection diseases of livestock as well as preparation method and application thereof | |
| EP2832370A1 (en) | Method for producing drugs and biologically active agents | |
| RU2527042C1 (en) | Biologically active food additive for osteoporosis prevention | |
| Ernst et al. | How Does Immunomodulatory Nanoceria Work? ROS and Immunometabolism | |
| EL Barky et al. | Detoxifying and antioxidant effect of ellagic acid nano particles in rats intoxicated with sodium nitrites | |
| JP7048167B2 (en) | Treatment of lifestyle-related diseases Water and treatment methods for lifestyle-related diseases | |
| RU2452498C2 (en) | Method for preparing anti-tuberculosis drug | |
| CN111529549A (en) | Antibacterial and antiviral high-valence electrolytic silver ion solution and preparation method thereof | |
| JP3824604B2 (en) | Zinc-containing substance having antioxidative action | |
| JP2010265209A (en) | Iodine liquid preparation | |
| JP3519991B2 (en) | Method for producing neutral silver ionized water | |
| JP2014200778A (en) | Antioxidative drinking water | |
| Xiong et al. | Selenium Yeast Mitigates Diquat-Induced Oxidative Stress in Rooster Testicles and Preserves Reproductive Performance | |
| Gowda et al. | Fluorosis: an endemic toxicity, mode of action and methods of amelioration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150713 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160425 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160518 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160803 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160803 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5991543 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |